Journal article

Towards the biomarker-guided rational use of antiangiogenic agents in the treatment of metastatic colorectal cancer

Michael M Halford, Niall C Tebbutt, Jayesh Desai, Marc G Achen, Steven A Stacker

Colorectal Cancer | Future Medicine Ltd | Published : 2012


SUMMARY Clinical oncology experience with recently marketed antiangiogenic agents, which inhibit proteins important for tumor angiogenesis, has exposed significant limitations to their efficacy. Bevacizumab, a humanized neutralizing anti-VEGF-A monoclonal antibody, used in combination with cytotoxic chemotherapy for the treatment of metastatic colorectal cancer, represents the best-studied clinical example of targeted antiangiogenic therapy. In this context, bevacizumab provides modestly improved progression-free and overall survival in unselected patient populations via poorly understood mechanisms. Here we review concepts central to the identification and development of biomarkers in order..

View full abstract